Long‐term use of lokivetmab in dogs with atopic dermatitis

Kasper, Bettina ; Zablotski, Yury und Mueller, Ralf S. (2024): Long‐term use of lokivetmab in dogs with atopic dermatitis. In: Veterinary Dermatology, Bd. 35, Nr. 6: S. 683-693

Abstract

Background: Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD).

Objectives: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.

Animals: 150 dogs with cAD.

Materials and Methods: Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.

Results: Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.

Conclusion and Clinical Relevance: Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Tiermedizin > Zentrum für Klinische Tiermedizin > Klinik für Wiederkäuer mit Ambulanz und Bestandsbetreuung
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0959-4493
• Sprache: Englisch